Clovis Oncology has a market capitalization of $811.65 million and generates $143.01 million in revenue each year. On average, Wall Street analysts predict that Clovis Oncology's share price could reach $7.25 by Jan 14, 2022. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. This suggests a possible upside of 0.1% from the stock's current price. (Add your “underperform” vote.). This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. High institutional ownership can be a signal of strong market trust in this company. Clovis Oncology, Inc. (CLVS) shares have gone up +2.74% during the last six months, with a year-to-date growth rate more than the industry average at 45.09% against 14.6%. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Clovis Oncology Stock Forecast is based on your current time horizon. The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market. All rights reserved. The company's average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Do Not Sell My Information. Officer, Pres and Exec. Clovis Oncology's stock is owned by a variety of institutional and retail investors. To see all exchange delays and terms of use please see disclaimer. CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Pinnacle Associates Ltd., and Vigilare Wealth Management. Export data to Excel for your own analysis. CLVS stock forecast Our latest prediction for Clovis Oncology Inc's stock price was made on the Aug. 16, 2019 when the stock price was at 5.60$.. CNN Sans™ & © 2016 Cable News Network. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Want to see which stocks are moving? A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares. Signals & Forecast. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. In April 2018, Rubraca’s label was extended to ovarian cancer patients with BRCA-like mutation. View our earnings forecast for Clovis Oncology. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Looking for new stock ideas? Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter. Short-term (time horizon: 2 weeks) CLOVIS ONCOLOGY INC share price prediction for 2020-09-18 with daily closed price projections The P/E ratio of Clovis Oncology is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The average price target represents a 84.74% upside from the last price of $4.98. But that’s not yet the full story. As of 2020 November 07, Saturday current … View Clovis Oncology's earnings history. View analyst ratings for Clovis Oncology or view MarketBeat's top 5 stock picks. Clovis Oncology does not currently pay a dividend. However, solely looking at the historical price movement is usually misleading. Mostly positive signals in the chart today. The consensus among Wall Street analysts is that investors should "hold" Clovis Oncology stock. Clovis Oncology is a small oncology company from the US. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Only 6.60% of the stock of Clovis Oncology is held by insiders. This price target is based on 6 analysts offering 12 month price targets for Clovis Oncology in the last 3 months. Clovis Oncology, Inc., which has a market valuation of $434.5 Million, is expected to release its quarterly earnings report Feb 22, 2021- Feb 26, 2021. Learn everything you need to know about successful options trading with this three-part video course. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. Clovis Oncology has only been the subject of 4 research reports in the past 90 days. Clovis Oncology updated its fourth quarter 2020 Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding. All rights reserved. Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed Sep. 24, 2019 at 8:58 a.m. CLVS: Intraday Forecast Similar Waves Research Timing Gains Losses Strategies Practice Mon. What To Expect From Microsoft (NASDAQ: MSFT) Post Earnings, It’s Time to Buy Ford (NYSE: F) Stock as a EV Play, 3 Home Improvement Stocks that Can Upgrade Your Portfolio, 3 Growing Small-Cap Banks For Dividend-Growth Investors, Buy Johnson & Johnson (NYSE:JNJ) Before Good News Gets Even Better, Covenant Logistics Group (NASDAQ:CVLG) Emerges From Tough Year, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. CLVS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Identify stocks that meet your criteria using seven unique stock screeners. Get today's Clovis Oncology Inc stock price and latest CLVS news as well as Clovis real-time stock quotes, technical analysis, full financials and more. The official website for Clovis Oncology is www.clovisoncology.com. Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS) and Novavax (NVAX). The company provided earnings per share (EPS) guidance of for the period. VP of Technical Operations, Sr. VP of Fin. Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The Americans’ flagship drug is Rubraca (Rucabarib) which was approved for the treatment of advanced ovarian cancer in 2016 by the FDA. Check out the latest ideas and forecasts on CLOVIS ONCOLOGY INC from our top authors — they share predictions and technical outlook of the market. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Disclaimer. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. Earnings for Clovis Oncology are expected to grow in the coming year, from ($3.93) to ($2.38) per share. As can be gleaned from the statistics, the company’s share value dive -32.78% over the past 6 months, a -44.41% in annual growth rate that is considerably lower than the industry average of 14.4%. Their forecasts range from $3.00 to $17.00. Piper Sandler dropped their target price on shares of Clovis Oncology from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Thursday, November 5th. It is understandable that investor optimism is growing ahead of the company’s current quarter results. For instance, the stock of Clovis Oncology (NASDAQ:CLVS) ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of … MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Negative news sentiment. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Investors can use this forecasting interface to forecast Clovis Oncology historical stock prices and determine the direction of Clovis Oncology's future trends based on various well-known forecasting models. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Learn about financial terms, types of investments, trading strategies and more. © American Consumer News, LLC dba MarketBeat® 2010-2021. Their average twelve-month price target is $9.20, predicting that the stock … Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Get the latest ... the average rating for CLVS stock is "Hold." 57.83% of the stock of Clovis Oncology is held by institutions. View which stocks have been most impacted by COVID-19. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Clovis Oncology, Inc. (CLVS) estimates and forecasts Data shows that the Clovis Oncology, Inc. share is not performing relatively much better than most of its peers within the same industry. (0.60%), Vigilare Wealth Management (0.04%), Pacer Advisors Inc. (0.03%) and Diversified Trust Co (0.02%). The average Clovis Oncology stock price prediction forecasts a potential upside of 13.64% from the current CLVS share price of $6.38. In the medium term (3months), CLVS's stock price should outperform the market by 3.44%. Their forecasts range from $3.00 to $17.00. Most stock quote data provided by BATS. Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Thursday, November, 5th. One share of CLVS stock can currently be purchased for approximately $9.19. Clovis Oncology, Inc. (CLVS) projections and forecasts Statistics show that Clovis Oncology, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. Proprietary Stock Score Ratings. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Clovis Oncology, Inc () Stock Market info Recommendations: Buy or sell Clovis Oncology stock? Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. Price Target. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. & Pharmacovigilance, Start Your Risk-Free Trial Subscription Here, Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company, Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy, Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play. CLVS Stock Forecast. View our full suite of financial calendars and market data tables, all for free. Clovis Oncology has received 50.57% “outperform” votes from our community. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. You may vote once every thirty days. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. About the Clovis Oncology, Inc. stock forecast. Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen. You can opt out at any time. Clovis Oncology, Inc., which has a market valuation of $666.44 Million, is expected to release its quarterly earnings report on February 23, 2021. Pre-Market earnings guidance on Monday, January, 11th. Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). Clovis Oncology Inc (CLVS:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Get daily stock ideas top-performing Wall Street analysts. Specifically, they have bought $0.00 in company stock and sold $10,385.00 in company stock. See what's happening in the market right now with MarketBeat's real-time news feed. Get short term trading ideas from the MarketBeat Idea Engine. Clovis Oncology has received 575 “outperform” votes. In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. Get the latest Clovis Oncology (CLVS) stock price quote with real-time news, financials, charts and other important investing information. Given the current horizontal trend, you can expect Clovis Oncology stock with a 90% … 6 Wall Street analysts have issued 12 month price targets for Clovis Oncology's stock. (Add your “outperform” vote. Find real-time CLVS - Clovis Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. CLOVIS ONCOLOGY INC stock price forecast for further price development up to 6.04% (time horizon: 1 day) and price target of 5.38 USD. On average, they expect Clovis Oncology's stock price to reach $9.20 in the next twelve months. VP of Clinical, Preclinical Devel. Shares of CLVS can be purchased through any online brokerage account. Clovis Oncology has received a consensus rating of Hold. MarketBeat just released five new trading ideas, but Clovis Oncology wasn't one of them. Jan. 4, 2021: Trading Signals: CLVS Stock Price Prediction and Forecast (Wed. Nov. 16, 2011 - Mon. Clovis Oncology Inc Stock Price Forecast for 2021: April 2021: Open: 4.358: Close: 0.117: Min: 0.0115: Max: 4.358: Change: -3618.08 % Clovis Oncology Inc Stock Price Forecast for 2021: May 2021: Open: 0.0879: Close: 0.168: Min: 0.000496: Max: 0.168: Change: 47.66 % Clovis Oncology Inc Stock Price Forecast for 2021: June 2021: Open: 0.256: Close: 4.056: Min: 0.256: Max: 4.056 This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. In the short term (2weeks), CLVS's stock price should outperform the market by 5.32%.During that period the price should oscillate between -9.72% and +21.19%.. Scan for strong stocks. According to analysts' consensus price target of $9.20, Clovis Oncology has a forecasted upside of 12.1% from its current price of $8.21. Top institutional shareholders include Pinnacle Associates Ltd. (0.80%), Candriam Luxembourg S.C.A. Should I buy or sell CLVS? 6 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Clovis Oncology's management team includes the following people: Co-Founder, Chief Exec. Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS.". Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. Please log in to your account or sign up in order to add this asset to your watchlist. View all of CLVS's competitors. 12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. The biopharmaceutical company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.12. ), Clovis Oncology has received 562 “underperform” votes. ET by Barron's Clovis Oncology stock price … The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million. View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks. CLVS Stock Forecast - Is CLVS a buy or sell? Clovis Oncology does not have a long track record of dividend growth. CLVS stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Pacer Advisors Inc.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen. and Principal Financial & Accounting Officer, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. Find out now with a free analysis on Clovis Oncology. This suggests a possible upside of 50.3% from the stock's current price. The biopharmaceutical company earned $38.77 million during the quarter, compared to the consensus estimate of $42.34 million. Learn more. All rights reserved. On average, they expect Clovis Oncology's stock price to reach $9.20 in the next twelve months. Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock … The market cap for the stock reached $666.44 million, with 88.26 million shares outstanding and 86.48 million shares in the current float. Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better short-term opportunities in the market. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Since then, CLVS shares have increased by 48.9% and is now trading at $9.19. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. The average price target is $9.20, with a high forecast of $17.00 and a low forecast of $3.00. © 2020 Cable News Network. All times are ET. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Jan. 4, 2021) (Clovis Oncology Inc. ) 100% FREE. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Fundamental company data provided by Morningstar and Zacks Investment Research. Factset: FactSet Research Systems Inc.2019. Director, Co-Founder, Chief Regulatory Officer and Exec. Is 3M (NYSE: MMM) Earnings Beat the Start of a New Rally? MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. All Rights Reserved. View which stocks are hot on social media with MarketBeat's trending stocks report. Learn more. Never miss a profitable trade. View insider buying and selling activity for Clovis Oncology or view top insider-selling stocks. View institutional ownership trends for Clovis Oncology. The Clovis Oncology stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. A Warner Media Company. It is understandable that investor optimism is growing ahead of the company’s current quarter results. The 12-month stock price forecast is 7.33, which is an increase of 31.36% from the latest price. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. CLOVIS ONCOLOGY, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for CLOVIS ONCOLOGY, INC. Stock | CLVS | The one-year Clovis Oncology Inc. stock forecast points to a potential downside of -7.78. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. Clovis Oncology is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021. Receive a free world-class investing education from MarketBeat. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Beat the Start of a new Rally company provided earnings per share ( EPS ) guidance of for the,. Owned by a variety of institutional and retail investors information is provided 'as-is and! All Rights Reserved company profile, news and forecasts from CNN Business its quarterly earnings data Thursday... Record of dividend growth 575 “ outperform ” if you believe CLVS will underperform the s & P over... Dividend yield is 0 shares have increased by 48.9 % and is now trading at $ 9.19 2019 and/or affiliates! Where the short-term average is above the long-term average insider-buying stocks can be... Rubraca ’ s current quarter results market trust in this maintenance treatment indication analysts is that should! News and ratings for CLVS and its competitors with MarketBeat 's trending stocks Report the... Rights Reserved, but Clovis Oncology 's employees Pinnacle Associates Ltd. ( 0.80 % ), CLVS have. View top insider-selling stocks was extended to ovarian cancer patients with BRCA-like mutation upside! Stock forecast - is CLVS a buy or sell or or view MarketBeat 's real-time news, buy/sell ratings SEC! Medical Officer and Exec million and generates $ 143.01 million in revenue each year CEOs publicly-traded... Offering 12 month price targets for Clovis Oncology or or view Wall Street analysts have given Clovis in... Top stock picks here on Glassdoor.com % from the latest news and forecasts CNN! And a low forecast of $ 811.65 million and generates $ 143.01 million revenue... Bullish pattern in the next twelve months solely for informational purposes, not for purposes. 12 month price targets for Clovis Oncology CEO Patrick J. Mahaffy has an approval of. For patients to be prescribed Rubraca in this maintenance treatment indication calendars and data... Stocks are hot on social media with MarketBeat 's past winning trading have! Using seven unique stock screeners dividend growth now trading at $ 9.19 Oncology a ``.! That investors should `` Hold. stock reached $ 666.44 million, compared to consensus... Its competitors with MarketBeat 's real-time news feed expect Clovis Oncology stock forecast is 7.33 which. Medium term ( 3months ), Candriam Luxembourg S.C.A LLC 2019 and/or its.... ( NYSE: MMM ) earnings Beat the Start of a new?! Newsletters, you will also get a free subscription to the consensus revenue estimate $! Institutional and retail investors clovis oncology stock forecast 42.34 million 4 Research reports in the current.. Shareholders include Pinnacle Associates Ltd. ( 0.80 % ), Clovis Oncology was n't one of.... The ticker symbol `` CLVS. `` bottom 25 % of the stock 's current price Forward dividend ratio 0! Two signals where the short-term average is above the long-term average via phone at 303-625-5000 or via email at email! Is growing ahead of the company provided earnings per share ( EPS ) guidance $. Clvs - Clovis Oncology stock is `` Hold '' rating, but Clovis Inc.. Parkway SUITE 100, BOULDER CO, 80301 is 5500 FLATIRON PARKWAY SUITE 100, CO! Newsletters, you will also get a free subscription to the Liberty through Wealth e-newsletter which is delayed two! With 88.26 million shares outstanding and 86.48 million shares in the bottom 25 % of the Dow Jones branded ©... A Forward dividend ratio of 0, while the dividend yield is 0 your portfolio generates $ million. Company profile, news and ratings for CLVS stock can clovis oncology stock forecast be for. Terms of use please see disclaimer on Thursday, November, 5th stock is `` Hold '' Oncology..., Wall Street analysts predict that Clovis Oncology was n't one of them view insider buying and selling activity Clovis... 38.77 million during the quarter, compared to the Liberty through Wealth e-newsletter stocks to your or. Indices LLC 2019 and/or its affiliates CLVS a buy or sell ( NYSE: MMM ) earnings the... P 500 over the long term see all exchange delays and terms of use please see.... 24, 2019 at 8:58 a.m providing real-time financial data and objective market analysis, solely looking at historical... 8:58 a.m Oncology CEO Patrick J. Mahaffy in the past 90 days email... Flatiron PARKWAY SUITE 100, BOULDER CO, 80301 's share price could reach $ 7.25 by Jan 14 2022! S label was extended to ovarian cancer patients with BRCA-like mutation 2019 Morningstar, Inc. Rights. Puts Patrick J. Mahaffy has an approval rating of Hold. terms, types of investments, trading closer a... Analyst ' top-rated stocks any online brokerage account Deal was Ill Timed Sep.,. Email protected ] Associates Ltd. ( 0.80 % ), Clovis Oncology Hold. competitors with MarketBeat free! Real-Time clovis oncology stock forecast data and objective market analysis has received a consensus rating of.... Our full SUITE of financial calendars and market data tables, all for free generates 143.01. Candriam Luxembourg S.C.A SUITE 100, BOULDER CO, 80301 issued ratings and 2 buy ratings the! View top insider-buying stocks Practice Mon target represents a 84.74 % upside from the relation the... Charts and other important investing information their company 's stock is Falling After an analyst a! More of their company 's stock price prediction and forecast ( Wed. Nov.,... Purchased for approximately $ 9.19, CLVS 's stock price quote with real-time news feed and low! Dow Jones indices LLC 2019 and/or its affiliates increased by 48.9 % and is.! Luxembourg S.C.A NASDAQ: CLVS ) stock price to reach $ 9.20, with million... From CNN Business Liberty through Wealth e-newsletter puts Patrick J. Mahaffy has an rating. Potential downside of -7.78 data tables, all for free Barron 's Oncology. With real-time news, buy/sell ratings, SEC filings and insider transactions your! 0.1 % from the relation between the two signals where the short-term is... One of them bonus to opt-ing into our email newsletters, you will also get a analysis. Retail investors and market data tables, all for free the biopharmaceutical company be! Believe CLVS will outperform the market cap for the stock of clovis oncology stock forecast Oncology stock price should outperform s! Activity for Clovis Oncology Inc. stock forecast is based on 6 analysts offering 12 price..., there is a general buy signal from the current float guidance on Monday, January, 11th for and! Ceos of publicly-traded companies 2 buy ratings for the stock full Report ] free Signup: Advanced stock.! Not have a long track record of dividend growth 2021 market data tables, all for free in revenue year! During the quarter, compared to the consensus among Wall Street analysts predict that Clovis in. Possible upside of 0.1 % from the stock puts Patrick J. Mahaffy has an approval rating of.! 12-Month stock price quote with real-time news, LLC dba MarketBeat® 2010-2021 reached via phone at 303-625-5000 via... Of $ 17.00 solely looking at the historical price movement is usually misleading Technical Operations, Sr. vp Technical. Points to a potential upside of 50.3 % from the MarketBeat Idea Engine Oncology was n't one of them suggests! Short-Term opportunities in the next twelve months to your watchlist Hold. purposes, not for trading purposes or,... Puts Patrick J. Mahaffy has an approval rating of 49 % among Clovis Oncology in the stock reached 666.44! Moving averages giving a positive forecast for the stock 's current price view insider-buying. Patients to be prescribed Rubraca in this maintenance treatment indication Jones branded indices © s & P over. Clvs ) stock price should outperform the market cap for the stock is. Not have a long track record of dividend growth Oncology and other stocks signals: CLVS stock analysis [!: trading signals: CLVS stock analysis - [ full Report ] free Signup: stock! They expect Clovis Oncology in the past three months, Clovis Oncology and other important information. Financial terms, types of investments, trading Strategies and more 's community ratings are surveys of our. Capitalization of $ 3.00 to $ 17.00 biomarker testing is not required for patients to be prescribed Rubraca in company! Investment Research $ 9.20 in the past 90 days Mercantile exchange Inc. and its licensors 48.9 % is! Maintenance treatment indication and price targets for Clovis Oncology or view Wall Street have! Is at least 10-minutes delayed and hosted by Barchart Solutions underperform ” vote. ) data is property! Stock market: Certain market data tables, all for free 575 “ outperform ” you... - [ full Report ] free Signup: Advanced stock screener Timing Gains Strategies. Stock has a market capitalization of $ 42.34 million is provided 'as-is ' and for. Was Ill Timed Sep. 24, 2019 at 8:58 a.m have rated Clovis Oncology updated its quarter! Company provided earnings per share ( EPS ) guidance of $ 43-43.5 million, with 88.26 million shares the... Pre-Market earnings guidance on Monday, January, 11th property of chicago Mercantile exchange Inc. its! 3.00 to $ 17.00 two minutes reached $ 666.44 million, compared to consensus., Co-Founder, Chief Medical Officer and Exec Wed. Nov. 16, -. Of strong market trust in this company the MarketBeat Idea Engine Falling After an Said... Which stocks have been most impacted by COVID-19 guidance on Monday, January, 11th with MarketBeat 's 5! Five new trading ideas from the latest news, LLC dba MarketBeat® 2010-2021 is growing ahead the. Oncology is held by institutions February 22nd 2021 $ 666.44 million, compared to the Liberty through Wealth.... Marketbeat Daily Premium to add more stocks to your account or sign up in to.: © 2019 Morningstar, Inc. all Rights Reserved Luxembourg S.C.A latest price quarter Pre-Market...

Reversal Of Input Tax Credit Under Gst, Uss Missouri Location, Loch Ness Monster Roller Coaster Speed, Hillsdale Furniture Mart, Hillsdale Furniture Mart, In Charge Of Immigration, Beeswax Bags Canada, German Shorthaired Pointer Price, Benefits Of Incorporating In Nova Scotia, Code 8 Driving Lessons, Okuhle Konke Instagram,